With Previous Treatment vs Without Previous Treatment: Risk Factors for the Proportion of Responders of Tolterodine-Previous Treatment

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

Measures 6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

Measure	Value	95% interval, lower	95% interval, upper	Method	Source
Risk in group 1	0.74	0.711	0.767	wilson	ClinicalTrials.gov
Risk in group 2	0.854	0.845	0.862	wilson	ClinicalTrials.gov
Risk difference, group 1 minus group 2	-0.114	-0.144	-0.0856	newcombe hybrid score	ClinicalTrials.gov
Risk ratio, group 1 over group 2	0.867	0.833	0.901	log	ClinicalTrials.gov
Odds ratio, group 1 over group 2	0.487	0.415	0.572	log	ClinicalTrials.gov
Number needed to treat, for one fewer participant with the outcome on With Previous Treatment than on Without Previous Treatment	8.78	6.95	11.7	from the risk difference interval	ClinicalTrials.gov

Groups 2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

Group	Title	Description	With the outcome	Analysed	ClinicalTrials.gov code	Source
Group 1	With Previous Treatment	Participants with previous treatment of OAB who took tolterodine according to Japanese Package Insert.	698	943	OG000	ClinicalTrials.gov
Group 2	Without Previous Treatment	Participants without previous treatment of OAB who took tolterodine according to Japanese Package Insert.	5,753	6,736	OG001	ClinicalTrials.gov

Outcome 5

Field	Value	Source
Type	SECONDARY	ClinicalTrials.gov
Title	Risk Factors for the Proportion of Responders of Tolterodine-Previous Treatment	ClinicalTrials.gov
Description	Number of participants with response to tolterodine to determine whether with or without previous treatment is significant risk factor.	ClinicalTrials.gov
Time frame	12 week	ClinicalTrials.gov
Population	The efficacy analysis population consists of the evaluable cases in accordance with the analysis plan (cases judged to have been evaluated appropriately).	ClinicalTrials.gov

Trial 8

Field	Value	Source
Title	Tolterodine Drug Use Investigation.(Post Marketing Commitment Plan)	ClinicalTrials.gov
NCT number	NCT01488578	ClinicalTrials.gov
Phases		ClinicalTrials.gov
Conditions	Overactive Bladder	ClinicalTrials.gov
Interventions	Tolterodine tartrate	ClinicalTrials.gov
Lead sponsor	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	ClinicalTrials.gov
Results first posted	2012-06-14	ClinicalTrials.gov
Results on ClinicalTrials.gov	https://clinicaltrials.gov/study/NCT01488578?tab=results	ClinicalTrials.gov

Source 4

Field	Value	Source
Release	trial-comparisons-2026-03-23-0.1.0	ClinicalTrials.gov
Release manifest SHA-256	f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57	ClinicalTrials.gov
AACT copy	2026-03-23	ClinicalTrials.gov
Tables read	outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet	ClinicalTrials.gov

The same record as JSON

Release trial-comparisons-2026-03-23-0.1.0

ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.